Literature DB >> 18033320

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients.

A Mazumder, J Kaufman, R Niesvizky, S Lonial, D Vesole, S Jagannath.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18033320     DOI： 10.1038/sj.leu.2405035

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  34 in total

1.  Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.

Authors:  Shaji K Kumar; Martha Q Lacy; Suzanne R Hayman; Keith Stewart; Francis K Buadi; Jacob Allred; Kristina Laumann; Philip R Greipp; John A Lust; Morie A Gertz; Steven R Zeldenrust; P Leif Bergsagel; Craig B Reeder; Thomas E Witzig; Rafael Fonseca; Stephen J Russell; Joseph R Mikhael; David Dingli; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Am J Hematol       Date:  2011-05-31       Impact factor: 10.047

2.  Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.

Authors:  S Afifi; N G Adel; S Devlin; E Duck; J Vanak; H Landau; D J Chung; N Lendvai; A Lesokhin; N Korde; L Reich; O Landgren; S Giralt; H Hassoun
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

Review 3.  Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.

Authors:  M Mohty; K Hübel; N Kröger; M Aljurf; J Apperley; G W Basak; A Bazarbachi; K Douglas; I Gabriel; L Garderet; C Geraldes; O Jaksic; M W Kattan; Z Koristek; F Lanza; R M Lemoli; L Mendeleeva; G Mikala; N Mikhailova; A Nagler; H C Schouten; D Selleslag; S Suciu; A Sureda; N Worel; P Wuchter; C Chabannon; R F Duarte
Journal:  Bone Marrow Transplant       Date:  2014-03-31       Impact factor: 5.483

Review 4.  Novel Induction Regimens in Multiple Myeloma.

Authors:  Karie D Runcie; Tomer M Mark
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 5.  How best to use new therapies in multiple myeloma.

Authors:  David Dingli; S Vincent Rajkumar
Journal:  Blood Rev       Date:  2010-04-01       Impact factor: 8.250

Review 6.  Controversies in multiple myeloma: to transplant or not?

Authors:  Isabel Ruth Preeshagul; Koen Van Besien; Tomer M Mark
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

7.  Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.

Authors:  Susan Bal; Heather J Landau; Gunjan L Shah; Michael Scordo; Parastoo Dahi; Oscar B Lahoud; Hani Hassoun; Malin Hultcrantz; Neha Korde; Nikoletta Lendvai; Alexander M Lesokhin; Sham Mailankody; Urvi A Shah; Eric Smith; Sean M Devlin; Scott Avecilla; Ahmet Dogan; Mikhail Roshal; Ola Landgren; Sergio A Giralt; David J Chung
Journal:  Biol Blood Marrow Transplant       Date:  2020-05-19       Impact factor: 5.742

8.  Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma.

Authors:  M A Gertz; S K Kumar; M Q Lacy; A Dispenzieri; S R Hayman; F K Buadi; D Dingli; D A Gastineau; J L Winters; M R Litzow
Journal:  Bone Marrow Transplant       Date:  2008-11-10       Impact factor: 5.483

Review 9.  Front-line treatment in younger patients with multiple myeloma.

Authors:  S Vincent Rajkumar; Pieter Sonneveld
Journal:  Semin Hematol       Date:  2009-04       Impact factor: 3.851

10.  Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.

Authors:  Uday Popat; Rima Saliba; Rupinderjit Thandi; Chitra Hosing; Muzaffar Qazilbash; Paolo Anderlini; Elizabeth Shpall; John McMannis; Martin Körbling; Amin Alousi; Borje Andersson; Yago Nieto; Partow Kebriaei; Issa Khouri; Marcos de Lima; Donna Weber; Sheeba Thomas; Michael Wang; Roy Jones; Richard Champlin; Sergio Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2009-04-08       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.